Medicines Co. wins interim patent extension; Sepracor grants Glenmark Lunesta license;

@FiercePharma: FDA slaps Novartis for Facebook widget. Article | Follow @FiercePharma

> Medicines Co. said the U.S. Patent and Trademark Office granted a one-year interim patent extension for its lead drug Angiomax, after a federal judge ruled that the patent office has to consider the company's extension application. Report

> Roche's Avastin helps patients with the most common form of lung cancer live longer than any other treatment, a new trial showed, giving the drug a boost after a slew of setbacks. News

> Glenmark Pharmaceuticals signed a settlement and license agreement with Sepracor to market a generic version of its sleep drug Lunesta. Story

> Sixty-three percent of surveyed gastroenterologists in the U.S. say they are prescribing Abbott/Eisai's blockbuster arthritis treatment Humira (adalimumab) off-label for the treatment of ulcerative colitis. Item

> Medicis Pharmaceutical said its second-quarter profit more than doubled as sales soared for the drug company's acne products. Article

> Sanofi-Aventis has once again selected contract manufacturing organisation SCM Pharma for the fast-tracked fill/finish of a radio-labeled product. Story

Biotech News

 @FierceBiotech: GSK licenses Vectura's inhalation tech for $32 million. Article | Follow @FierceBiotech

 @JohnCFierce: Another example of a weak biotech IPO. NuPathe cuts price from $14 to $16 to $10. Article | Follow @JohnCFierce

> Did the odds just get worse for Arena's new weight drug? Story

> Curis shares sink as Genentech evaluates lead drug's fate. Article

> Lambda snags Biovail's Toronto CRO. Story

Biotech IT News

> Online tool aid patient access to experimental drugs. News

> Adaptive trial modeling solution aids dose-finding. Report

> Michigan researchers to gain in IT makeover. Item

> Mayo Clinic to launch center for social media. Story

> Healthcare reform drives investor to IT opportunities. Article

> FDA, Tox21 try IT in place of animal tests. Item

And Finally... Pfizer may have turned around Wall Street's negative sentiment toward its pharmaceutical fortunes with one good quarter. Report